Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
2013 for the treatment of mantle cell lymphoma
(2013) Mol Cancer Ther
InChi: InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H
Potent PAR2 biased agonist
Meropenem ethoxy-PEPy 2013 for the treatment ofMeropenem is an ultra broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem and Meronem. Other brand names include Zwipen (India, Marketed by Nucleus) Mepem
US$ 397.50
US$ 190.89
US$ 312.50